12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CNDO-109: Phase I final data

Final data from a Phase I trial showed that 3 of 5 evaluable patients experienced a longer subsequent complete response after receiving a single IV infusion of CNDO-109 tumor-primed NK cells compared to their previous complete response. Specifically, the median duration of complete response post-infusion was...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >